BioSpace News Archive

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,096,933 titled “Method of Treating Disorders Associated with Chronic Inflammation.”

Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in Cancer Prevention Research, a journal of the American Association for Cancer Research.

Tarsier Pharma today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe .

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that it has entered into an option agreement (“Option”) with The Texas A&M University System (“TAMUS”) for exclusive rights to the intellectual property covering highly potent main protease (MPro) inhibitors against SARS-CoV-2.

As part of its commitment to investing in translational science that significantly improves the lives of patients, UPMC has launched Novasenta, a drug discovery and development company seeking novel and effective treatments for cancer.

Biocom California Appoints Bernard Parker as New Vice Chair of Diversity, Equity and Inclusion and Appoints Charles Dadswell as Chairman of Newly Formed Public Policy Advisory Committee

Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy (CUNY SPH) have been awarded a five-year, $14.5 million grant from the National Institutes of Health (NIH)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “the Group"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its interim results for the first half of 2021 (“the Reporting Period”).

The Alzheimer Society of Canada has announced an investment of more than three million dollars in funding, that will support 26 dementia researchers and their teams across Canada .

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company will be present at the following investor events: H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021